Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Acuitas Therapeutics Inc. maintains a portfolio in the Biotechnology & Pharmaceuticals technology area with 7 pending office actions. The prosecution workload is spread across 7 distinct examiners, meaning no individual examiner is currently handling multiple pending actions for the company. This distribution spans 5 distinct art units, showing a relatively broad organizational footprint at the patent office. The variety of art units suggests that the company's pharmaceutical innovations touch upon several different technical classifications.
PO-CHIH CHEN is the busiest examiner assigned to the portfolio, though this role involves only 1 pending office action. Because there are 7 distinct examiners for 7 total actions, the workload is evenly distributed across the personnel. Practitioners should note that while the art unit count is 5, the examiner count is higher at 7, suggesting diverse technical sub-specialties even within the same art units. This structure requires the company to manage relationships with a high number of individual examiners relative to the total volume of pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (14%) |
| Multi-statute (no §101) | 6 (86%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.2% | +14.8% |
| HIRT, ERIN E | 1 | 40.3% | +23.0% |
| ROSENTHAL, ANDREW S | 1 | 51.8% | +38.7% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.8% | +30.2% |
| PACKARD, BENJAMIN J | 1 | 66.7% | +15.6% |
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| POPA, ILEANA | 1 | 21.4% | +15.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744241 | AMIDE CONTAINING LIPIDS | ROSENTHAL, ANDREW S | 18d overdue |
| 18902591 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | CHEN, PO-CHIH | — |
| 18767373 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | HIRT, ERIN E | — |
| 18421751 | mRNA THERAPY WITH REDUCED IMMUNE REACTOGENICITY | ALSOMAIRY, SARAH ABDOALATIF | — |
| 18462141 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PACKARD, BENJAMIN J | — |
| 17634516 | IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | BLUMEL, BENJAMIN P | — |
| 17496530 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744241 | AMIDE CONTAINING LIPIDS | ROSENTHAL, ANDREW S | 18d overdue |
| 18902591 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | CHEN, PO-CHIH | — |
| 18767373 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | HIRT, ERIN E | — |
| 18421751 | mRNA THERAPY WITH REDUCED IMMUNE REACTOGENICITY | ALSOMAIRY, SARAH ABDOALATIF | — |
| 18462141 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PACKARD, BENJAMIN J | — |
| 17634516 | IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | BLUMEL, BENJAMIN P | — |
| 17496530 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1613 | 1 |
| 1612 | 1 |
| 1671 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18902591 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | CHEN, PO-CHIH | — | §103§112Other | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18767373 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | HIRT, ERIN E | 1616 | §102§103§112Other | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18744241 | AMIDE CONTAINING LIPIDS | ROSENTHAL, ANDREW S | 1613 | §103§112 | Final Rejection | 18d overdue | Pending | Jun 14, 2024 |
| 18421751 | mRNA THERAPY WITH REDUCED IMMUNE REACTOGENICITY | ALSOMAIRY, SARAH ABDOALATIF | — | §102§103§112 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18462141 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PACKARD, BENJAMIN J | 1612 | §102§103 | Non-Final OA | — | Pending | Sep 06, 2023 |
| 17634516 | IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | BLUMEL, BENJAMIN P | 1671 | §102§112Other | Final Rejection | — | Pending | Feb 10, 2022 |
| 17496530 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | 1633 | DP | Final Rejection | — | Pending | Oct 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial